Skandinaviska Enskilda Banken AB publ cut its stake in shares of Shire PLC (NASDAQ:SHPG) by 12.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,695 shares of the biopharmaceutical company’s stock after selling 9,500 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Shire PLC were worth $11,795,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in SHPG. Bedell Frazier Investment Counseling LLC increased its stake in Shire PLC by 15.2% in the first quarter. Bedell Frazier Investment Counseling LLC now owns 26,068 shares of the biopharmaceutical company’s stock valued at $4,542,000 after buying an additional 3,430 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Shire PLC by 45.3% in the first quarter. Tower Research Capital LLC TRC now owns 1,122 shares of the biopharmaceutical company’s stock valued at $195,000 after buying an additional 350 shares during the last quarter. New South Capital Management Inc. bought a new stake in shares of Shire PLC during the first quarter valued at $87,954,000. FNY Partners Fund LP increased its stake in shares of Shire PLC by 7,336.7% in the first quarter. FNY Partners Fund LP now owns 35,101 shares of the biopharmaceutical company’s stock valued at $6,115,000 after buying an additional 34,629 shares in the last quarter. Finally, Janus Capital Management LLC increased its stake in shares of Shire PLC by 10.7% in the first quarter. Janus Capital Management LLC now owns 1,365,226 shares of the biopharmaceutical company’s stock valued at $237,854,000 after buying an additional 132,446 shares in the last quarter. Institutional investors own 20.93% of the company’s stock.
Shares of Shire PLC (NASDAQ:SHPG) traded down 0.44% during mid-day trading on Wednesday, hitting $171.15. The stock had a trading volume of 416,421 shares. The firm’s 50-day moving average price is $176.62 and its 200 day moving average price is $174.09. The stock has a market cap of $50.98 billion, a price-to-earnings ratio of 175.54 and a beta of 1.57. Shire PLC has a 12-month low of $161.09 and a 12-month high of $209.22.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.22 by $0.41. Shire PLC had a return on equity of 13.05% and a net margin of 2.14%. The firm had revenue of $3.57 billion during the quarter. During the same period in the prior year, the business earned $2.12 earnings per share. The company’s revenue for the quarter was up 109.0% on a year-over-year basis. Equities analysts forecast that Shire PLC will post $14.90 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Shire PLC (SHPG) Shares Sold by Skandinaviska Enskilda Banken AB publ” was first reported by sleekmoney and is the property of of sleekmoney. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://sleekmoney.com/shire-plc-shpg-shares-sold-by-skandinaviska-enskilda-banken-ab-publ/1946552.html.
Several equities research analysts recently weighed in on SHPG shares. Barclays PLC started coverage on Shire PLC in a report on Tuesday, March 7th. They set an “overweight” rating for the company. Liberum Capital started coverage on Shire PLC in a report on Thursday, March 9th. They set a “buy” rating for the company. Royal Bank Of Canada reaffirmed a “buy” rating and set a $221.00 price target on shares of Shire PLC in a report on Tuesday, March 14th. Jefferies Group LLC set a $239.00 price target on Shire PLC and gave the stock a “buy” rating in a report on Saturday, March 18th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “focus list” rating on shares of Shire PLC in a report on Tuesday, March 21st. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and sixteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $223.01.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/shire-plc-shpg-shares-sold-by-skandinaviska-enskilda-banken-ab-publ/1946552.html
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.